Dianthus Therapeutics (DNTH) Insider Trading & Ownership $18.42 +0.46 (+2.57%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Dianthus Therapeutics (NASDAQ:DNTH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.56%Number OfInsiders Buying(Last 3 Years)2Amount OfInsider Buying(Last 3 Years)$1.31MNumber OfInsiders Selling(Last 3 Years)0 Get DNTH Insider Trade Alerts Want to know when executives and insiders are buying or selling Dianthus Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DNTH Insider Buying and Selling by Quarter Dianthus Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/29/2023Fairmount Funds Management LlcDirectorBuy24,670$13.63$336,252.10 9/26/2023Fairmount Funds Management LlcDirectorBuy30,000$13.15$394,500.00 9/21/2023Simrat RandhawaInsiderBuy2,000$13.20$26,400.00 9/19/2023Fairmount Funds Management LlcDirectorBuy30,000$13.20$396,000.00 9/12/2023Fairmount Funds Management LlcDirectorBuy14,887$10.85$161,523.95 (Data available from 1/1/2013 forward) DNTH Insider Trading Activity - Frequently Asked Questions Who is on Dianthus Therapeutics' Insider Roster? The list of insiders at Dianthus Therapeutics includes Fairmount Funds Management Llc, and Simrat Randhawa. Learn more on insiders at DNTH. What percentage of Dianthus Therapeutics stock is owned by insiders? 16.56% of Dianthus Therapeutics stock is owned by insiders. Learn more on DNTH's insider holdings. Which Dianthus Therapeutics insiders have been buying company stock? The following insiders have purchased DNTH shares in the last 24 months: Fairmount Funds Management Llc ($1,288,276.05), and Simrat Randhawa ($26,400.00). How much insider buying is happening at Dianthus Therapeutics? Insiders have purchased a total of 101,557 DNTH shares in the last 24 months for a total of $1,314,676.05 bought. More Insider Trading Tools from MarketBeat Related Companies Arrowhead Pharmaceuticals Insider Trades Apellis Pharmaceuticals Insider Trades Twist Bioscience Insider Trades Vericel Insider Trades NewAmsterdam Pharma Insider Trades Denali Therapeutics Insider Trades Kiniksa Pharmaceuticals International Insider Trades Recursion Pharmaceuticals Insider Trades Apogee Therapeutics Insider Trades CG Oncology Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold?3 Hot Trades for Insiders, But Are They Good Buys for Investors?Insiders Chase Income and Stability in American Tower—Here’s Why3 Tech Stocks With High and Rising Institutional Interest This page (NASDAQ:DNTH) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
